-+ 0.00%
-+ 0.00%
-+ 0.00%
Virax Biolabs Presents Plans for 2027 U.S. Diagnostic Testing Launch
Share
Listen to the news
Virax Biolabs Presents Plans for 2027 U.S. Diagnostic Testing Launch
  • Virax Biolabs targets a 2027 U.S. laboratory-developed test launch through a proposed hosted laboratory model, retaining assay ownership and testing revenue rights.
  • A potential FDA De Novo submission is targeted for 2028.
  • Results from the 160-participant UK study are delayed beyond the first quarter of 2027; analysis awaits assay finalization.
  • Cash totaled $5.12 million at September 30, 2026; targeted cumulative cost savings reach approximately $2.4 million through March 2028.
  • Exploratory pilot testing reported 88% specificity and 92% positive predictive value for post-acute infection syndromes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending